Erectile dysfunction

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Retrieved on:

Donnerstag, Juni 6, 2024

Acquisition, ODT, Marketing, Infection, Opposition, Entrepreneurship, Patent, Weight loss, Urinary tract infection, Pharynx, Common, Erectile dysfunction, HPV, Zinc, Pharmaceutical industry

Acceptance of the application will officially be published in the Australian Official Journal of Patents on June 6, 2024.

Key Points:

Acceptance of the application will officially be published in the Australian Official Journal of Patents on June 6, 2024.
Jacob Cohen, Co-Founder and CEO of MangoRx commented, “Receiving this Notice of Acceptance in Australia is yet another critical step in our strategy to protect and commercialize our innovative preventive care technology on a global basis.
It further underscores our commitment to expanding our reach and providing advanced preventive care solutions to a broader audience.
Receiving a patent issuance in Australia would join an already robust portfolio of U.S. and international patents, reinforcing MangoRx’s position of becoming a leader in the preventive health sector.

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

Retrieved on:

Dienstag, Juni 4, 2024

Acquisition, ODT, Marketing, Infection, Entrepreneurship, Patent, Weight loss, Urinary tract infection, Pharynx, Common, Erectile dysfunction, HPV, Zinc

This significant milestone follows MangoRx’s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies.

Key Points:

This significant milestone follows MangoRx’s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies.
The US patent (Patent 11,517,523) was initially applied for by Intramont and subsequently acquired by MangoRx on April 24, 2024, further expanding the global protection for its groundbreaking preventive care technology.
Jacob Cohen, Co-Founder and CEO of MangoRx, expressed his enthusiasm about this achievement: “Receiving this Notice of Allowance in Japan is a critical step in our global strategy to protect and commercialize our innovative preventive care technology.
The Notice of Allowance in Japan joins an already robust portfolio of U.S. and international patents, reinforcing MangoRx’s position of becoming a leader in the preventive health sector.

MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

Retrieved on:

Dienstag, Juni 4, 2024

Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone (DHEA) in an Oral Dissolvable Tablet (ODT) aimed at restoring hormonal balance and naturally increasing testosterone levels in men. The new compounded product will be named “MOJO” and sold exclusively on MangoRx’s website on a subscription basis at a price of $199 per month.

Key Points:

DHEA: A precursor hormone that supports overall hormonal balance, DHEA is linked to improvements in energy levels, mood, and general well-being.
Pregnenolone: Known as the “mother hormone,” Pregnenolone plays a crucial part in the production of other essential hormones and supports cognitive and mental health.
"Our new Enclomiphene citrate formulation, MOJO, represents a significant breakthrough in the treatment of male hormonal imbalances," said Jacob Cohen, Co-Founder and CEO of MangoRx.
MOJO leverages and features the synergistic effects of Enclomiphene citrate, DHEA, and Pregnenolone to address these issues effectively and safely, setting a new standard in male hormonal therapy.

Posterity Health Expands Hormone Management Program Across the US: Helping Every Male Feel Their Best

Retrieved on:

Mittwoch, Juni 5, 2024

In recognition of Men’s Health Month, Posterity Health, the Center of Excellence for Male Care, proudly announces the launch of its innovative Hormone Management Program.

Key Points:

In recognition of Men’s Health Month, Posterity Health, the Center of Excellence for Male Care, proudly announces the launch of its innovative Hormone Management Program.
The Posterity Health Male Management Platform (MMP) combines innovative technology, expert care teams and AI driven clinical protocols to drive personalized end-to-end male care.
The service expansion reinforces our commitment to making male health care more accessible," said Pam Pure, Founder and CEO at Posterity Health.
For more information about the Posterity Health Hormone Management program or to schedule a consultation, visit https://posterityhealth.com/services/hormone-management/ or contact 720-666-4739.

Top Los Angeles Urologist Dr. Justin Houman's Clinic Designated as a Center of Excellence for Testicular Pain and Orchialgia

Retrieved on:

Donnerstag, Juni 13, 2024

LOS ANGELES, June 13, 2024 /PRNewswire-PRWeb/ -- Dr. Justin Houman, a leading expert in men's health and urology, proudly announces that his clinic has been officially designated as a Center of Excellence for Testicular Pain and Orchialgia. This prestigious recognition underscores Dr. Houman's commitment to providing exceptional care and innovative treatments for men suffering from chronic testicular pain.

Key Points:

LOS ANGELES, June 13, 2024 /PRNewswire-PRWeb/ -- Dr. Justin Houman, a leading expert in men's health and urology , proudly announces that his clinic has been officially designated as a Center of Excellence for Testicular Pain and Orchialgia.
This prestigious recognition underscores Dr. Houman's commitment to providing exceptional care and innovative treatments for men suffering from chronic testicular pain .
Spermatic Cord Denervation: For patients experiencing chronic orchialgia or testicular pain, spermatic cord denervation offers a targeted approach to pain relief.
Recognized as a Testicular Pain and Orchialgia Center of Excellence, his clinic offers state-of-the-art treatments including microsurgical procedures and minimally invasive surgeries.

The Urology Care Foundation Encourages Men to Take Charge of Their Health, One Checkup at A Time, For Men’s Health Month

Retrieved on:

Freitag, Mai 31, 2024

BALTIMORE, May 31, 2024 (GLOBE NEWSWIRE) -- June starts Men’s Health Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is encouraging men to take charge of their health, one checkup at a time.

Key Points:

BALTIMORE, May 31, 2024 (GLOBE NEWSWIRE) -- June starts Men’s Health Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is encouraging men to take charge of their health, one checkup at a time.
But cancers are not the only urological issues men should be getting checked out; for men, urology includes the entire urinary tract and reproductive organs.
Once these problems are diagnosed, men can partner with a men's health specialist to get things back on the right track.
For more information on all aspects of men’s health, view the Urology Care Foundation’s Men’s Health Month Info Center.

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

Retrieved on:

Dienstag, Mai 28, 2024

API, USD, Marketing, Certification, Erectile dysfunction, ED, Weight loss, Active ingredient

These ODTs contain the Active Pharmaceutical Ingredient (API) Tadalafil and maintain the same exceptional flavor as MangoRx's other ED products.

Key Points:

These ODTs contain the Active Pharmaceutical Ingredient (API) Tadalafil and maintain the same exceptional flavor as MangoRx's other ED products.
The initial batch is currently undergoing testing by a third-party U.S. laboratory to ensure consistency and quality.
“This achievement marks a significant milestone in our expansion into the Mexican and Latin American markets,” stated Jacob Cohen, MangoRx’s Co-Founder and CEO.
This will further pave the way for obtaining the necessary certification to begin marketing and selling Mango ED products across Mexico.

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

Retrieved on:

Donnerstag, Mai 23, 2024

DTC, CPA, Digital, Health, Marketing, Acquisition, Erectile dysfunction, Weight loss, Telehealth, Entrepreneurship, Video game

Based in Quebec City, Canada, Crakmedia is a leader in performance marketing, web development and traffic monetization.

Key Points:

Based in Quebec City, Canada, Crakmedia is a leader in performance marketing, web development and traffic monetization.
Digital ads on the Crakmedia network are seen up to 1.5 billion times a day in over 150 countries and territories.
The company will also use Crakmedia's owned and operated cost-per-acquisition (CPA) network to manage its affiliate marketing program.
“With over 150 dedicated employees, Crakmedia has an extremely successful track record in marketing men’s health and wellness direct-to-consumer (DTC) companies.

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

Retrieved on:

Dienstag, Mai 21, 2024

Patient, Obesity, Overalls, Drug development, Health, Marketing, Injection, Erectile dysfunction, Weight loss, Alpha, History, Entrepreneurship, Pharmaceutical industry

Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRx’s new oral formulations are poised to revolutionize the weight loss market and capture significant market share.

Key Points:

MangoRx’s new oral formulations are poised to revolutionize the weight loss market and capture significant market share.
The oral formulations of Semaglutide and Tirzepatide are set to capture a significant share of this market, offering a convenient alternative to injections.
Patient preference studies consistently show a significant majority in favor of oral medications over injectables.
“We are thrilled to introduce ‘Slim’ and ‘Trim’, MangoRx’s oral formulations of Semaglutide and Tirzepatide, to the weight loss market,” said Jacob Cohen, CEO and Co-Founder of MangoRx.

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

Retrieved on:

Donnerstag, Mai 16, 2024

Pharmacy, Telehealth, Men's Health, Health, Acquisition, Marketing, Entrepreneurship, Patent, Erectile dysfunction, Pharmaceutical industry

This revenue growth demonstrates a positive trajectory for the company's financial performance in Q1 2024.

Key Points:

This revenue growth demonstrates a positive trajectory for the company's financial performance in Q1 2024.
In addition to achieving significant revenue growth, MangoRx has strategically advanced its customer acquisition and revenue expansion efforts.
The company launched a direct-to-clinic sales division enabling medical professionals to prescribe MangoRx products directly from their offices, clinics, and wellness facilities.
This unique approach is expected to bolster recurring revenue channels while minimizing customer acquisition costs typically associated with conventional digital marketing strategies.